Lesinurad

What is Lesinurad?[edit | edit source]

Lesinurad (ZURAMPIC) is a URAT1 inhibitor used to treat high blood uric acid levels associated with gout.

This medicine is used together with a xanthine oxidase inhibitor to lower uric acid levels in the blood in adult patients with gout.
ZURAMPIC should not be taken without a xanthine oxidase inhibitor such as allopurinol or febuxostat.
ZURAMPIC helps the kidneys remove uric acid from the body and is added to a xanthine oxidase inhibitor, which decreases the amount of uric acid your body makes.

Lesinurad (le sin' ure ad) is a selective inhibitor of the uric acid transporter (URAT1) in the kidneys that is responsible for reabsorption or urate in the distal tubules.
Inhibition of uric acid reabsorption causes a decrease in serum levels of uric acid, but an increase in urinary urate.
Lesinurad was found to lower uric acid levels in patients with gout and hyperuricemia who had not achieved adequate control of symptoms or uric acid levels with a xanthine oxidase inhibitor (allopurinol or febuxostat) alone.

This medicine cannot be used in patients who have:

severe kidney problems, received a kidney transplant or you are on dialysis
a fast breakdown of cancer cells that can lead to high uric acid (Tumor lysis syndrome)
a rare inherited condition that causes too much uric acid in the blood (Lesch Nyhan syndrome)

ZURAMPIC should be used with caution in patients taking moderate inhibitors of CYP2C9 (eg, fluconazole, amiodarone), and in CYP2C9 poor metabolizers).
Lesinurad exposure is decreased when ZURAMPIC is co-administered with moderate inducers of CYP2C9 (eg, rifampin, carbamazepine), which may decrease the therapeutic effect of ZURAMPIC.
ZURAMPIC should not be administered with inhibitors of epoxide hydrolase(eg: valproic acid).
Females should practice additional methods of contraception and not rely on hormonal contraception alone when taking ZURAMPIC.
Aspirin at doses higher than 325 mg per day may decrease the efficacy of ZURAMPIC in combination with allopurinol.

Recommended Dosage:

ZURAMPIC is recommended at 200 mg once daily in combination with a xanthine oxidase inhibitor, including allopurinol or febuxostat. The maximum daily dose of ZURAMPIC is 200 mg
Failure to take ZURAMPIC with a xanthine oxidase inhibitor may increase the risk of renal adverse reactions.

Patients with Renal Impairment

No dose adjustment is needed in patients with mild or moderate renal impairment (eCLcr of 45 mL/min or greater).
ZURAMPIC should not be initiated in patients with an eCLcr less than 45 mL/min.
Assessment of renal function is recommended prior to initiation of ZURAMPIC therapy and periodically thereafter.
ZURAMPIC should be discontinued when eCLcr is persistently less than 45 mL/min.

Administration

Take ZURAMPIC exactly as your healthcare provider tells you to take it.
Take 1 ZURAMPIC tablet in the morning with your dose of xanthine oxidase inhibitor such as allopurinol or febuxostat. Do not take more than 1 ZURAMPIC tablet each day.
Take ZURAMPIC with food and water.
Drink 2 liters (68 ounces) of fluid each day to stay hydrated.
If you miss taking the dose of ZURAMPIC in the morning, do not take ZURAMPIC later in the day. Wait and take your next dose of ZURAMPIC in the morning with your dose of xanthine oxidase inhibitor such as allopurinol or febuxostat.
Do not double your dose of ZURAMPIC.
Your gout may get worse (flare up) when you first start taking ZURAMPIC. Do not stop taking ZURAMPIC even if you have a flare. Your healthcare provider may give you other medicines to help prevent your gout flares.
Your healthcare provider may do blood tests to check how well your kidneys are working before and during your treatment with ZURAMPIC.

This medicine is available in fallowing doasage form: As Tablet: 200 mg

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

ZURAMPIC may cause serious side effects, including:

Avoid taking ZURAMPIC alone. This could increase your risk of kidney problems. ZURAMPIC should always be taken together with a xanthine oxidase inhibitor such as allopurinol or febuxostat.
Avoid becoming dehydrated while taking ZURAMPIC.
Adverse reactions related to renal function have occurred after initiating ZURAMPIC. A higher incidence was observed at the 400 mg dose, with the highest incidence occurring with monotherapy use. Monitor renal function at initiation and during therapy with ZURAMPIC, particularly in patients with eCLcr below 60 mL/min, and evaluate for signs and symptoms of acute uric acid nephropathy.
Major adverse cardiovascular events were observed with ZURAMPIC; a causal relationship has not been established.

Management of overdosage:

In case of overdose patients should be managed by symptomatic and supportive care including adequate hydration.

There are no available human data on use of ZURAMPIC in pregnant women to inform a drug-associated risk.

Safety and effectiveness in pediatric patients under 18 years of age have not been established.

Active ingredient: lesinurad
Inactive ingredients: lactose monohydrate, microcrystalline cellulose, hypromellose, crospovidone, and magnesium stearate.

Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington
Manufactured by: AstraZeneca AB, S-151 85 Sodertalje, Sweden; Product of Ireland

ZURAMPIC is a trademark of the AstraZeneca group of companies.

Lesinurad Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.